Biosimilar Humira® (adalimumab) and Enbrel® (etanercept) – FDA Advisory Committee recommendations
July 12-13, 2016 – The FDA held Advisory Committee meetings to discuss Amgen’s ABP 501, a proposed biosimilar to AbbVie's Humira (adalimumab) and Sandoz’s GP2015, a proposed biosimilar to Amgen’s Enbrel (etanercept).
Top